#progression-free-survival
#progression-free-survival

[ follow ]

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations | NEJM

Sunvozertinib first-line therapy improved progression-free survival and objective response versus carboplatin-pemetrexed in advanced EGFR exon 20 insertion NSCLC, with higher grade 3+ adverse events.

[ Load more ]

#progression-free-survival#progression-free-survival

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations | NEJM

#progression-free-survival
#progression-free-survival